Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial

U.S.-listed shares of Oncolytics Biotech ONCY.O rise 5.7% to $1.09 premarket

Co says it has reached an agreement with the U.S. FDA on the design of a major clinical trial for its experimental cancer drug, pelareorep, in patients with advanced pancreatic cancer

Pancreatic cancer is an aggressive disease with limited treatment options; trial aims to add immunotherapy to standard chemo - ONCY

ONCY says main goal is overall survival

Co says study will compare chemo alone vs. chemo plus pelareorep, with an option to add another type of cancer drug called a checkpoint inhibitor

Pelareorep has shown promise in earlier pancreatic and breast cancer studies; both programs have FDA Fast Track status - ONCY

Up to last close, stock up 13% YTD